The sharp revenue decline and reliance on non-recurring milestones make the legacy product business difficult to value, but the $33.1M capital raise and patent extension de-risk SGT-610 through its Phase 3 readout in Q4 2026. Traders should watch for top-line results from the Gorlin syndrome trial, which is the primary catalyst; a positive readout could re-rate the stock significantly, while a miss would likely erase the post-offering premium.
Price Chart
Executive Summary
Sol-Gel reported Q1 2026 revenue of $0.1M (down 89.5% YoY from $1.0M) and a net loss of $3.7M ($1.31/share), improved from a $8.8M loss in Q1 2025. The company highlighted a Notice of Allowance for a method-of-use patent extending SGT-610 protection to 2044, an oversubscribed $33.1M offering, and an exclusive license agreement with Sun Pharma for TWYNEO in India. Cash and marketable securities totaled $52.8M, funding operations into Q1 2028.
Key Facts
- Q1 2026 revenue was $0.1M, down from $1.0M in Q1 2025, primarily due to the absence of a milestone payment from Searchlight.
- Net loss improved to $3.7M ($1.31/share) from $8.8M ($3.2/share) in Q1 2025, driven by a $6.0M reduction in R&D expenses.
- Cash, cash equivalents, and marketable securities totaled $52.8M as of March 31, 2026, up from $24.0M at year-end 2025.
- Completed an oversubscribed underwritten offering in March 2026, raising gross proceeds of approximately $33.1M.
- Received a Notice of Allowance from the USPTO for a method-of-use patent covering topical patidegib (SGT-610), extending IP protection to 2044.
- Pivotal Phase 3 trial of SGT-610 for Gorlin syndrome remains on track for top-line results in Q4 2026.
- Signed an exclusive license agreement with Sun Pharma for TWYNEO commercialization in India.
- Shares outstanding increased from 2,786,158 at December 31, 2025 to 3,268,991 at March 31, 2026, reflecting dilution from the offering.
- Management expects TWYNEO and EPSOLAY launches in most new territories during 2028 and 2027, respectively, with potential annual royalty revenue of ~$10M by 2031.
Financial Impact
Revenue declined $0.9M YoY; net loss improved by $5.1M; cash position increased by $28.8M from year-end 2025 due to $33.1M offering; share count increased ~17% from the offering.
Risk Factors
- Phase 3 trial failure or delay would severely impact the stock, as SGT-610 is the primary value driver.
- Revenue from legacy products (TWYNEO/EPSOLAY) remains minimal and unpredictable, with launches not expected until 2027-2028.
- Dilution from the March 2026 offering (~17% increase in shares outstanding) weighs on per-share metrics.
- Cash runway only extends to Q1 2028, requiring further financing if SGT-610 commercialization is delayed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-002963 |
| Document: zk2635418.htm | 0001178913-26-002963 |
| Document: 0001178913-26-002963-index-headers.html | 0001178913-26-002963 |
| Document: 0001178913-26-002963-index.html | 0001178913-26-002963 |
| Document: 0001178913-26-002963.txt | 0001178913-26-002963 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | 6-K | $75.64 | awaiting T+20 | — | $69.63 (−7.95%) |
Sep 30, 2026 26d ago | 6-K | $74.28 | awaiting T+20 | — | $69.63 (−6.26%) |
Sep 17, 2026 5w ago | 6-K | $64.54 $68.70 | ▲ +6.45% | ▲ +4.99% | $69.63 (+7.89%) |
Sep 14, 2026 6w ago | Insider Buy | $64.40 $68.30 | ▲ +6.06% | ▲ +3.08% | $69.63 (+8.12%) |
Sep 9, 2026 6w ago | Insider Buy | $66.79 $70.34 | ▲ +5.32% | ▲ +2.94% | $69.63 (+4.25%) |
Sep 3, 2026 7w ago | Insider Buy | $69.52 $78.95 | ▲ +13.56% | ▲ +12.96% | $69.63 (+0.16%) |
Aug 31, 2026 8w ago | Insider Buy | $69.52 $74.28 | ▲ +6.85% | ▲ +6.53% | $69.63 (+0.16%) |
Aug 20, 2026 9w ago | 6-K | $78.50 $64.54 | ▼ −17.78% | ▼ −17.78% | $69.63 (−11.29%) |
Aug 20, 2026 9w ago | Press Release | $78.50 $64.54 | ▼ −17.78% | ▼ −17.78% | $69.63 (−11.29%) |
Aug 14, 2026 10w ago | Insider Buy | $83.01 $64.40 | ▼ −22.42% | ▼ −20.44% | $69.63 (−16.12%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers